Assessing the safety and pharmacokinetics of casirivimab and imdevimab (CAS+IMD) in a cohort of pregnant outpatients with COVID-19: results from an adaptive, multicentre, randomised, double-blind, phase 1/2/3 study
Thomas D Norton, Mazhar Thakur, Samit Ganguly, Shazia Ali, Jesse Chao, Alpana Waldron, Jing Xiao, Yogesh Patel, Kenneth C Turner, John D Davis, Susan C Irvin, Cynthia Pan, Dominique Atmodjo-Watkins, Andrea T Hooper, Jennifer D Hamilton, Danise Subramaniam, Joseph A Bocchini, Bari Kowal, A. Thomas DiCioccio, Rafia Bhore, Gregory P Geba, Edward Cox, Ned Braunstein, Paula Dakin, Gary A Herman
BMJ Open Oct 2024, 14 (10) e087431; DOI: 10.1136/bmjopen-2024-087431